Mexico Gel Column Agglutination Test System Market Size & Outlook, 2026-2034
Mexico Gel Column Agglutination Test System Market Insights
- As highlighted in Reed Intelligence analysis, the Mexico Gel Column Agglutination Test System Market, worth USD 44.07 Million in 2025, is forecasted to achieve USD 91.35 Million by 2034.
- The Mexico market is anticipated to grow at a CAGR of 8.46% during the period 2026–2034.
- By 2025, Instruments and Analyzers represented the largest share of the Product Type market size.
- Reagents and Gel Cards is expected to remain the key growth driver within Product Type, registering the fastest CAGR during the forecast period.
![Mexico Gel Column Agglutination Test System Market Size, Share & Growth Analysis By [2034]](https://reedintelligence.com/uploads/charts/mexico-gel-column-agglutination-test-system-market-mexico-product-type-132726.png)
Source: RI Analysis Company Publications, Primary Interviews.
Other Key Findings
- In 2025, Mexico represented 3.19% of the overall global Gel Column Agglutination Test System Market size.
- United States is projected to lead the global Gel Column Agglutination Test System Market size by 2034.
- Across LATAM, Brazil is anticipated to hold the dominant position in market size by 2034.
- Argentina is forecasted to expand at the fastest pace in LATAM, attaining USD 45.62 Million by 2034.
Report Summary
| Report Scope | Details |
|---|---|
| Base Year for Study | 2025 |
| Study Period | 2022-2034 |
| Historical Period | 2022-2024 |
| Forecast Period | 2026-2034 |
| Market Size In 2025 | USD 44.07 Million |
| Market Size In 2034 | USD 91.35 Million |
| Largest segment | Instruments and Analyzers |
| Units | Revenue in USD Million |
| CAGR | 8.46% (2026-2034) |
| Segmnetation Covered | |
| Product Type |
|
| Application |
|
| End User |
|
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends |
Mexico Gel Column Agglutination Test System Market Product Type 2026-2034 (USD Million)
| Product Type | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Instruments and Analyzers | XX.x | XX.x | XX.x | 17.71 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Reagents and Gel Cards | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Software and Accessories | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Consumables and Controls | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
Mexico Gel Column Agglutination Test System Market Application 2026-2034 (USD Million)
| Application | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Blood Typing and Cross-Matching | XX.x | XX.x | XX.x | 20.36 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Antibody Screening | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Compatibility Testing | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Other Immunohematology Tests | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
Mexico Gel Column Agglutination Test System Market End User 2026-2034 (USD Million)
| End User | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hospitals | XX.x | XX.x | XX.x | 19.66 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Blood Banks | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Diagnostic Laboratories | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Research Institutions | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Academic Medical Centers | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
